- Report
- January 2023
- 111 Pages
Asia Pacific
From €3269EUR$3,450USD£2,759GBP
- Report
- October 2022
- 159 Pages
Global
From €4217EUR$4,450USD£3,559GBP
- Report
- January 2024
- 200 Pages
Global
From €3933EUR$4,150USD£3,319GBP
- Report
- October 2023
- 145 Pages
Global
From €2985EUR$3,150USD£2,519GBP
- Report
- December 2023
- 250 Pages
Global
€4733EUR$4,995USD£3,995GBP
- Report
- May 2022
- 140 Pages
Global
From €3411EUR$3,600USD£2,879GBP
- Report
- October 2021
- 200 Pages
Global
From €3790EUR$4,000USD£3,199GBP
- Report
- October 2021
- 101 Pages
Global
From €3790EUR$4,000USD£3,199GBP
- Report
- January 2022
Global
From €7107EUR$7,500USD£5,998GBP
- Report
- January 2025
- 81 Pages
Global
From €3500EUR$3,957USD£3,057GBP
- Report
- August 2024
- 95 Pages
Global
From €3500EUR$3,957USD£3,057GBP
- Report
- January 2024
- 81 Pages
Global
From €3500EUR$3,957USD£3,057GBP
- Report
- August 2022
- 78 Pages
Global
From €3500EUR$3,957USD£3,057GBP
- Report
- May 2024
- 275 Pages
Global
From €3383EUR$3,570USD£2,855GBP
- Report
- April 2022
- 220 Pages
Global
From €3275EUR$3,456USD£2,764GBP
- Book
- January 2010
- 200 Pages

Left Ventricular Assist Devices (LVADs) are a specialized subgroup within the cardiovascular devices sector, aimed at supporting patients with advanced heart failure. These mechanical pumps are designed to aid or fully take over the function of the left ventricle, which is the main pumping chamber of the heart. LVADs are typically employed when medical therapy is insufficient, either as a bridge to heart transplantation, a destination therapy for those who are not candidates for a transplant, or increasingly, as a bridge to recovery, where the device supports the heart with the intention that the heart's function might improve to the point that the device can be removed.
The market for LVADs intersects with advancements in battery technology, materials science, and medical device engineering. Over the years, LVADs have progressed from large, volume-restrictive devices to more compact and less invasive units, improving the quality of life for patients. Adoption of these devices is influenced by factors such as the prevalence of heart failure, technological innovations, healthcare infrastructure, as well as reimbursement policies and regulatory approvals.
Some prominent companies in the LVAD market include Abbott Laboratories, which oversees the HeartMate product line, Medtronic, known for their portfolio of cardiac medical devices, and Berlin Heart, which provides options including Excor, a device designed for a range of patient sizes, including pediatric use. Other notable players include Thoratec, which was acquired by St. Jude Medical, itself later acquired by Abbott, and Jarvik Heart, known for Show Less Read more